Navigation Links
New Oral Anticoagulants Markets
Date:3/25/2013

oagulants 66
Table 3.19: Pharmacokinetic Parameters after Five Days of 1.5 mg/kg SC Once
Daily Doses of Enoxaparin Sodium Using 100 mg/mL or 200 mg/mL Concentrations 73
Table 3.20: Pharmacokinetic Parameters of Fondaparinux and Other Anticoagulants
74
Table 3.21: Composition of 20,000 Anti-Xa IU/mL Innohep 74
Table 3.22: Comparison of Characteristics of AVE5026, Idrabiotaparinux,
Otamixaban and RB006 76
Table 4.1: Comparison of Top Five Antiplatelets 83
Table 4.2: Estimated Yearly Incidence of Bleeding with Antiplatelets 85
Table 4.3: Summary of Evidence for Antiplatelets 86
Table 4.4: Cost of Antiplatelets 86
Table 4.5: Information on Ticagrelor 91
Table 4.6: Product Information on Clopidogrel 93
Table 4.7: CURE Incidence of Bleeding Complications (% Patients) 94
Table 4.8: Incidence of Bleeding Event in COMMIT (% Patients) 95
Table 5.1: Influence of Anticoagulants on Routine Coagulation Assays 99
Table 5.2: Influence of Anticoagulants on Thrombophilia Assays 99
Table 6.1: ACC/AHS Recommendations for Antiplatelet Therapy in Patients with
NSTEMI or UA 119
Table 6.2: Dosing of LMWH, Fondaparinux and Bivalirudin in Patients with NSTEMI
or UA 120
Table 6.3: ACC/AHA Recommendations for Anticoagulants Therapy in Patients with
NSTEMI or UA 120
Table 6.4: Antiplatelet Therapy in Patients with STEMI 121
Table 6.5: Anticoagulants Therapy in Patients with STEMI Who Receive
Fibrinolytic Therapy 121
Table 6.6: Anticoagulants Therapy in Patients with STEMI Who Undergo Primary PCI
122
Table 6.7: ACCP Recommendations for Thromboprophylactic Strategy Based on Risk
for VTE 122
Table 6.8: Anticoagulants Treatments for VTE 123
Table 6.9: Projections of Crude Cardiovascular Disease Prevalence, 2010-2030 125
Table 6.10: Projected Direct Medical Costs for Cardiovascular Diseases,
2010-2030 125
Table 6.11: Hamilton Score 131
Table 6.12:
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Global Anticoagulants Industry
2. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
3. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
4. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
5. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
6. MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016
7. Transdermal Hormone Replacement: Products, Players, Markets and Forecasts
8. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
9. Global Market for Medical Imaging Equipment to Reach $25.3 Billion as Retiring Boomers and Emerging Markets Demand Better Healthcare
10. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
11. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... FAIRFIELD, N.J. , July 30, 2015 /PRNewswire/ ... Ferrer, completed the second Phase III clinical study ... development for impetigo.  Medimetriks owns the exclusive U.S. ... The global trial, conducted at 44 centers with ... and pediatric patients aged 2 months and older ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Voreloxin Demonstrates Promising Clinical Activity in Patients with ... Difficult-to-Treat ... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) presented data from three ... the Chemotherapy Foundation Symposium held in New York on November ...
... 5 Medarex, Inc.,(Nasdaq: MEDX ) today ... of,an undisclosed amount from its licensing partner, Centocor ... trial of CNTO 95, a fully human antibody,targeting ... The CNTO 95 human antibody was generated using ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 2Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 3Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 4Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 5Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors 2
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... is a one-day event geared to patients and family members, medical professionals, and ... and regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t Just Age” will ... thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International at Foxwoods Resort ... 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and other management and ...
(Date:7/31/2015)... ... ... The Mount Sinai Health System will work with Columbia Care LLC, a ... treatments. The collaboration moves into the next phase with the recent decision by the ... licenses to produce and dispense medical marijuana. , Mount Sinai and Columbia Care ...
(Date:7/31/2015)... ... 2015 , ... Like nearly every other form of surgery, it shouldn't come ... effective and less intrusive and painful. Leading these advances in the United States ... currently stands as the only doctor in the United States who is qualified to ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2
... Better understanding of genetic, biological causes could lead more ... (HealthDay News) -- When people understand the genetics and ... blame those with the eating disorder for their illness, ... (UNC) study. , "This is a potentially important ...
... of women showed effect lasted long after program ended ... exercises can help relieve chronic neck pain, says a ... Care & Research . , Previous studies have produced ... pain, but there hasn,t been enough high-quality research to ...
... immune system should fight tumors, researchers say , , ... to fight ovarian and breast cancer are in ... their safety and effectiveness, researchers report. , The ... Coukos, an assistant professor at the University of ...
... The state,s most highly-respected minds in medicine and emergency ... to improve Missouri,s emergency response systems, JEFFERSON CITY, ... will meet Tuesday, January 15, 2008, to compile,recommendations for ... the mortality and morbidity associated with stroke and ST-Segment,Elevation ...
... With a continued focus on,quality and ... to focus on opportunities for streamlining processes ... functions for,manufacturing organizations, the majority of the ... centralization could provide several,worthwhile benefits, as found ...
... for Collective Bargaining, ,Prompt Pay,Legislation, WASHINGTON, Jan. ... of Inspector General (OIG) on independent pharmacy payments ... Hill and runs counter to,claims from the independent ... today., "This report will raise eyebrows among ...
Cached Medicine News:Health News:Science Could Erase Stigma of Anorexia 2Health News:Strength Training Eases Chronic Neck Pain 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 3Health News:Time Critical Diagnosis Task Force Convenes in Jefferson City 2Health News:Manufacturing Organizations Identify Efficiencies in Maintenance Functions 2Health News:PCMA: New Study on Independent Pharmacy Reimbursements Will 'Raise Eyebrows' on Capitol Hill 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: